Trials / Completed
CompletedNCT02707575
Cytokeratin 8 Level in Age-related Macular Degeneration
Cytokeratin 8 Level in Aqueous Humor, as a Prognostic Factor for Visual and Anatomical Outcomes After Ranibizumab (Lucentis) in Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 58 (actual)
- Sponsor
- Gangnam Severance Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes with exudative age-related macular degeneration (AMD) before therapy with intravitreal Ranibizumab, and identify associations with visual and anatomical outcome after treatment.
Detailed description
In this non-randomized, and open-label study, the investigators will prospectively evaluate 58 patients with treatment naive exudative age-related macular degeneration (AMD) who receive intravitreal ranibizumab injection. A mean volume of 0.1 ml of aqueous humor samples will be taken each time an intravitreal injection is indicated and performed. Cytokeratin 8 level in aqueous humor will be evaluated, and associations of baseline cytokeratin 8 level and visual (the best corrected visual acuity change) and anatomical (optical coherence tomography parameters) after Ranibizumab injection will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed. |
Timeline
- Start date
- 2016-04-26
- Primary completion
- 2018-03-12
- Completion
- 2018-04-23
- First posted
- 2016-03-14
- Last updated
- 2020-12-09
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02707575. Inclusion in this directory is not an endorsement.